Print
Email
Jacobs Engineering Group Inc. (JEC) filed Quarterly Report for the period ended 2011-12-30.
Jacobs Engineering Group Inc. has a market cap of $5.79 billion; its shares were traded at around $45.28 with a P/E ratio of 17.1 and P/S ratio of 0.6. Jacobs Engineering Group Inc. had an annual average earning growth of 13.5% over the past 10 years. GuruFocus rated Jacobs Engineering Group Inc. the business predictability rank of 3.5-star.
This is the annual revenues and earnings per share of JEC over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of JEC.
Highlight of Business Operations:
Total revenues for the first quarter of fiscal 2012 increased by $275.6 million, or 11.7%, to $2.63 billion compared to $2.36 billion for the first quarter of fiscal 2011.As shown above, revenues from Technical Professional Services for the three months ended December 30, 2011 increased $333.2 million, or 27.7%, to $1.5 billion from $1.2 billion for the corresponding period last year. This increase was attributable primarily to higher business volume among the Company's legacy operations combined with revenues earned by the Aker Entities. Revenues from Field Services for the three months ended December 30, 2011 decreased $57.6 million, or 5.0%, to $1.1 billion from $1.2 billion for the corresponding period last year. This decline was due primarily to the normal winding-down of construction activities on several projects combined with the timing of procurement of pass-through equipment and materials and is not indicative of any trend.
For the three months ended December 30, 2011, revenues from clients operating in the Chemicals and Polymers industries and markets increased $184.2 million, or 72.1%, to $439.5 million from $255.3 million for the corresponding period last year. This increase was due primarily to higher business volume among the Company's legacy operations combined with revenues earned by the Aker Entities.
For the three months ended December 30, 2011, revenues from clients operating in the Pharmaceuticals and Biotechnology industries and markets increased $33.6 million, or 35.1%, to $129.3 million from $95.7 million for the corresponding period last year. This increase was due primarily to projects relating to vaccine production facilities.
Direct costs of contracts for the first quarter of fiscal 2012 increased $185.6 million, or 9.2%, to $2.2 billion as compared to $2.0 billion for the corresponding period last year. Direct costs of contracts include all costs incurred in connection with and directly for the benefit of client contracts, including depreciation and amortization relating to assets used in connection with providing the services required by client projects. The level of direct costs of contracts may fluctuate between reporting periods due to a variety of factors including the amount of pass-through costs we incur during a period. On those projects where we are responsible for subcontract labor or third-party materials and equipment, we reflect the amounts of such items in both revenues and costs (and we refer to such costs as “pass-through costs”). On other projects, where the client elects to pay for such items directly and we have no associated responsibility for such items, these amounts are not considered pass-through costs and are, therefore, not reflected in either revenues or costs. To the extent that we incur a significant amount of pass-through costs in a period, our direct cost of contracts are likely to increase as well.
Subscribe RSS
